Metabolic Hub
Featured this Month
Everyday and sick day support for T2D
A practical patient tool outlining when to pausemedication and how to manage diabetes during illness.
T2D & Me: Booklet now available
Support newly diagnosed patients with approachable information on type 2 diabetes,including symptom awareness, lifestyle tips, anddaily management guidance.
Podcast: Expanded PBS Access for Dapagliflozin
Learn how recent PBS changes support earlier use of SGLT2 inhibitors in high-risk type 2 diabetes patients—beyond glycemic control.
Healthcare Professional Resources
Explore resources tailored to support your everyday practice.
T2D Management Guidelines
Australian Diabetes Society: Australian Type 2 Diabetes Glycaemic Management Algorithm
Australian Living Evidence Consortium: Australian Evidence-Based Clinical Guidelines for Diabetes
PBS update: What it means for your T2D patients
Dr Kean-Seng Lim discusses the recent dapagliflozin listing and how it may guide treatment conversations.
Optimising T2D care with SGLT2 inhibitors
Dr Ted Wu discusses clinical benefits, PBS access, and real-world use of SGLT2 inhibitors in type 2 diabetes management.
Podcast: Expanded PBS Access for Dapagliflozin
Learn how recent PBS changes support earlier use of SGLT2 inhibitors in high-risk type 2 diabetes patients—beyond glycemic control.
Multidisciplinary Care
Diabetes Dialogues Vol 2: Health checks for patients with T2D
Join Endocrinologist A/Prof Roger Chen and General Practitioner Professor Charlotte Hespe for a discussion about the health checks they regularly complete for their patients with type 2 diabetes.
Diabetes Dialogues Vol 3: Managing T2D through collaboration between primary and specialist care
Join Endocrinologist A/Prof Roger Chen and General Practitioner Professor Charlotte Hespe for a discussion about how primary and specialty care can work together effectively in diabetes management for the best patient outcomes.
Impact of Early Intervention in a Type 2 Diabetic Patient with CKD
Professor Serge Jabbour explains why acting early to manage declining renal function in your T2D patients is important and the role you can play to deliver better health outcomes.
The Relevance of CKD to the Endocrinologist’s T2D Patient
Professor Serge Jabbour considers the importance of managing declining kidney function and treating beyond glycaemic control in patients with T2D.
Evidence for Dapagliflozin in HF
Patient Resources
Access helpful resources to share with your patients.
Everyday and sick day support for T2D
A practical patient tool outlining when to pause medication and how to manage diabetes during illness.
T2D & Me Patient Booklet: So you have T2D?
Support newly diagnosed patients with approachable information on type 2 diabetes, including symptom awareness, lifestyle tips, and daily management guidance.
You might also be interested in
Cardiovascular Hub
Explore resources for the diagnosis and management of heart failure and cardiovascular disease.
Want to know more?
If you have any questions or would like to be kept updated on new training
resources please subscribe to our email newsletter or reach out below.
Patient Resources
Access helpful resources to share with your patients.
Sick Day Plan Patient Leaflet
Download a plan to help your patients with chronic kidney disease navigate illness, managing their medication and next steps with their healthcare professional team.
First Nations Patient Booklet
Access a booklet developed for Aboriginal and Torres Strait Islander people to help support their FORXIGA® treatment.
Type 2 Diabetes: The greatest challenge to Australia’s health system1
Featured this Month
Know the impact,
take action against T2D1
Adapted from Diabetes Australia. The State of the Nation 2024: The diabetes epidemic in Australia.
Diabetes Dialogues Vol 4: Holistic Goals in T2D
Join Endocrinologist A/Prof Roger Chen and General Practitioner Professor Charlotte Hespe for a discussion about how they consider the health of the patient beyond T2D and the management goals they set.
DECLARE, DAPA-CKD and DAPA-HF: Clinical Trial Explainer
Professor Serge Jabbour discusses the breadth of evidence for dapagliflozin across the DECLARE, DAPA-CKD and DAPA-HF trials and its use in the management of T2D, CKD and HFrEF.
Diabetes Dialogues Vol 1: Overarching Treatment Goals for T2D Management
Join Endocrinologist A/Prof Roger Chen and General Practitioner Professor Charlotte Hespe for a discussion about the goals they set for their patients with type 2 diabetes.